<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511353</url>
  </required_header>
  <id_info>
    <org_study_id>14.002</org_study_id>
    <secondary_id>2775</secondary_id>
    <secondary_id>6720</secondary_id>
    <nct_id>NCT02511353</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study</brief_title>
  <acronym>IVERMAL</acronym>
  <official_title>Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool School of Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In western Kenya the prevalence of malaria in &lt;5 year olds has fallen from 70% in 1997 to 40%
      in 2008, where it has now stagnated. Innovative approaches are needed to continue towards
      elimination. Ivermectin is a broad spectrum antiparasitic endectocide widely used for the
      control of onchocerciasis and lymphatic filariasis at a dose of 150-200 mcg/kg. Ivermectin at
      this dose has a potent, but short-lived effect for 6-11 days on mosquito survival,
      egg-laying, and parasite sporogony. Higher doses are needed to prolong its mosquitocidal
      effects. Previous studies have shown ivermectin is very well tolerated and safe even up to
      2,000 mcg/kg. This dose finding study will evaluate the transmission blocking effect of
      high-dose ivermectin to define the optimal dose for future use of ivermectin in combination
      with artemisinin-based combination therapy (ACT) for mass drug administration (MDA). It
      explores a research question of global relevance. A prolonged transmission blocking effect of
      ivermectin could have substantial consequences for malaria control in the next decades. The
      results are expected to inform national malaria control programs in malaria endemic
      countries, to inform WHO guidelines, and to contribute to the regulatory process.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mosquito survival</measure>
    <time_frame>Survival of mosquitoes at 14 days after feeding on blood taking from study participants who started the 3-day ivermectin and DP regimen 7 days earlier.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mosquito survival</measure>
    <time_frame>Survival of mosquitoes at each day up to day 21 or 28 after each feeding experiments performed at 0, 2 day+4h, 10, 14, 21, 28 days after start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with malaria clinical and parasitological treatment response</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of ivermectin</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of piperaquine</measure>
    <time_frame>Up to day 28.</time_frame>
    <description>Dihydroartemisinin-piperaquine is a combination drug. As dihydroartemisinin has a very short elimination time, only the AUC for the longer acting piperaquine component will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma Concentration (Cmax) of ivermectin</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma Concentration (Cmax) of piperaquine</measure>
    <time_frame>Up to day 28.</time_frame>
    <description>Dihydroartemisinin-piperaquine is a combination drug. As dihydroartemisinin has a very short elimination time, only the Cmax for the longer acting piperaquine component will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability as assessed by adverse events reported in a general toxicity questionnaire</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS adverse events</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin concentrations</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>At 52 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mydriasis quantitated by pupillometry</measure>
    <time_frame>Up to day 28.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin 300 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin 600 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin</intervention_name>
    <arm_group_label>ivermectin 300 mcg/kg</arm_group_label>
    <arm_group_label>ivermectin 600 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo for ivermectin.</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>ivermectin 300 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine</intervention_name>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>ivermectin 300 mcg/kg</arm_group_label>
    <arm_group_label>ivermectin 600 mcg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic, uncomplicated Plasmodium falciparum infection

          -  Positive malaria microscopy or malaria RDT (pLDH)

          -  Age: 18-50 years

          -  Provide written informed consent

          -  Agree to be able to travel to clinic on days: 1, 2, 7, 10, 14, 21, and 28

        Exclusion Criteria:

          -  Signs or symptoms of severe malaria

          -  Unable to provide written informed consent

          -  For women: pregnancy or lactation

          -  Hypersensitivity to ivermectin or DP

          -  QTc &gt;460 ms on ECG

          -  Body Mass Index (BMI) below 16 or above 32 kg/m2

          -  Haemoglobin concentration below 9 g/dL

          -  Taken ivermectin in the last month

          -  Taken dihydroartemisinin-piperaquine in the last 12 weeks

          -  Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African
             Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan

          -  History and/or symptoms indicating chronic illness

          -  Current use of tuberculosis or anti-retroviral medication

          -  Previously enrolled in the same study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menno R. Smit, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool School of Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feiko ter Kuile, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool School of Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jaramogi Oginga Odinga Teaching and Referral Hospital</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Res Protoc. 2016 Nov 17;5(4):e213.</citation>
    <PMID>27856406</PMID>
  </reference>
  <results_reference>
    <citation>Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 Mar 27. pii: S1473-3099(18)30163-4. doi: 10.1016/S1473-3099(18)30163-4. [Epub ahead of print]</citation>
    <PMID>29602751</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>plasmodium</keyword>
  <keyword>dihydroartemisinin-piperaquine</keyword>
  <keyword>ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

